FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2471123721> ?p ?o ?g. }

• W2471123721 abstract "Abstract Abstract 3991 The transcription factor Yin-Yang 1 (YY1) is a multi-functional DNA-binding protein which can activate, repress, or initiate transcription depending on the context in which it binds. We have previously reported that YY1 is a repressor for the death receptors Fas and DR5 as well as it regulates both chemo- and immuno- resistance in many tumors such as prostate carcinoma and lymphoma. YY1 has also been reported to be a prognostic factor for some cancers. Due to the inherent resistance of multiple myeloma (MM) cell lines to various cytotoxic drugs, we examined the expression levels of YY1 in both MM cell lines and bone marrow (BM)-derived MM tissues. Analysis for YY1 was performed by immunohistochemistry (IHC) and western blot. We found that, compared to normal peripheral blood mononuclear cells and normal bone marrow, the expression of YY1 was significantly upregulated in both the cell lines and patient-derived MM tissues. The expression of YY1 was distributed in both the cytoplasm and the nucleus. Further, the intensity and frequency of cells expressing YY1 in the nuclei of MM tissues were significantly higher among patients with progressive disease as compared to patients with stable disease. In order to ascertain the role of YY1 in the maintenance of drug resistance in MM, we hypothesized that, due to the overexpression of YY1 in MM, inhibition of YY1 expression and activity should lower the threshold of resistance and render the MM cells more sensitive to drug-induced apoptosis. This hypothesis was tested using the MM U266 cell line and the drugs bortezomib and melphalan as models. The inhibition of YY1 was done by knocking down YY1 following transfection with YY1 siRNA. Analysis of the transfected cells with YY1 siRNA, but not with control siRNA, inhibited YY1 expression as analyzed by IHC and western blot. The U266 cells were first transfected with YY1 siRNA or control siRNA for 48 hours and then treated with various concentrations of bortezomib (2.5 and 5.0 nM) or melphalan (10 and 20 μM) that were not toxic to the cells for 48 hours. The cells were analyzed for apoptosis by activation of the effector caspase 3. The findings demonstrate that YY1/siRNA-treated cells were sensitized to apoptosis by bortezomib or melphalan. Analysis of the underlying mechanism by which the inhibition of YY1 sensitizes the MM cells via regulation of the apoptotic pathways will be presented. We are also currently testing specific chemical inhibitors for YY1 that are being tested both in vitro and pre-clinically in mice. The present findings demonstrate that YY1 is a potential target for therapeutic intervention and the combination of YY1 inhibitors with non-toxic doses of bortezomib, melphalan or other cytotoxic drugs may be beneficial for the treatment of MM patients who are no longer responding to current treatments. Further, we propose that, based on our findings that the level and nuclear localization of YY1 dictates disease progression in a subset of patients, inhibition of YY1 with treatment may reduce the frequency of patients with progressive disease. *Contributed equally Disclosures: No relevant conflicts of interest to declare." @default.
• W2471123721 created "2016-07-22" @default.
• W2471123721 creator A5005405176 @default.
• W2471123721 creator A5011522973 @default.
• W2471123721 creator A5038431825 @default.
• W2471123721 creator A5039200796 @default.
• W2471123721 creator A5040835019 @default.
• W2471123721 creator A5055490703 @default.
• W2471123721 creator A5057287134 @default.
• W2471123721 creator A5068075065 @default.
• W2471123721 creator A5081790862 @default.
• W2471123721 creator A5082889084 @default.
• W2471123721 date "2011-11-18" @default.
• W2471123721 modified "2023-10-18" @default.
• W2471123721 title "Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan," @default.
• W2471123721 doi "https://doi.org/10.1182/blood.v118.21.3991.3991" @default.
• W2471123721 hasPublicationYear "2011" @default.
• W2471123721 type Work @default.
• W2471123721 sameAs 2471123721 @default.
• W2471123721 citedByCount "0" @default.
• W2471123721 crossrefType "journal-article" @default.
• W2471123721 hasAuthorship W2471123721A5005405176 @default.
• W2471123721 hasAuthorship W2471123721A5011522973 @default.
• W2471123721 hasAuthorship W2471123721A5038431825 @default.
• W2471123721 hasAuthorship W2471123721A5039200796 @default.
• W2471123721 hasAuthorship W2471123721A5040835019 @default.
• W2471123721 hasAuthorship W2471123721A5055490703 @default.
• W2471123721 hasAuthorship W2471123721A5057287134 @default.
• W2471123721 hasAuthorship W2471123721A5068075065 @default.
• W2471123721 hasAuthorship W2471123721A5081790862 @default.
• W2471123721 hasAuthorship W2471123721A5082889084 @default.
• W2471123721 hasConcept C101762097 @default.
• W2471123721 hasConcept C104317684 @default.
• W2471123721 hasConcept C150194340 @default.
• W2471123721 hasConcept C153911025 @default.
• W2471123721 hasConcept C190283241 @default.
• W2471123721 hasConcept C203014093 @default.
• W2471123721 hasConcept C2776364478 @default.
• W2471123721 hasConcept C2777478702 @default.
• W2471123721 hasConcept C2780007613 @default.
• W2471123721 hasConcept C2780108899 @default.
• W2471123721 hasConcept C502942594 @default.
• W2471123721 hasConcept C54355233 @default.
• W2471123721 hasConcept C62944979 @default.
• W2471123721 hasConcept C81885089 @default.
• W2471123721 hasConcept C86339819 @default.
• W2471123721 hasConcept C86803240 @default.
• W2471123721 hasConceptScore W2471123721C101762097 @default.
• W2471123721 hasConceptScore W2471123721C104317684 @default.
• W2471123721 hasConceptScore W2471123721C150194340 @default.
• W2471123721 hasConceptScore W2471123721C153911025 @default.
• W2471123721 hasConceptScore W2471123721C190283241 @default.
• W2471123721 hasConceptScore W2471123721C203014093 @default.
• W2471123721 hasConceptScore W2471123721C2776364478 @default.
• W2471123721 hasConceptScore W2471123721C2777478702 @default.
• W2471123721 hasConceptScore W2471123721C2780007613 @default.
• W2471123721 hasConceptScore W2471123721C2780108899 @default.
• W2471123721 hasConceptScore W2471123721C502942594 @default.
• W2471123721 hasConceptScore W2471123721C54355233 @default.
• W2471123721 hasConceptScore W2471123721C62944979 @default.
• W2471123721 hasConceptScore W2471123721C81885089 @default.
• W2471123721 hasConceptScore W2471123721C86339819 @default.
• W2471123721 hasConceptScore W2471123721C86803240 @default.
• W2471123721 hasLocation W24711237211 @default.
• W2471123721 hasOpenAccess W2471123721 @default.
• W2471123721 hasPrimaryLocation W24711237211 @default.
• W2471123721 hasRelatedWork W2007855098 @default.
• W2471123721 hasRelatedWork W2019112722 @default.
• W2471123721 hasRelatedWork W2057902579 @default.
• W2471123721 hasRelatedWork W2067029716 @default.
• W2471123721 hasRelatedWork W2313815949 @default.
• W2471123721 hasRelatedWork W2411795098 @default.
• W2471123721 hasRelatedWork W2509944253 @default.
• W2471123721 hasRelatedWork W2529809317 @default.
• W2471123721 hasRelatedWork W2555646772 @default.
• W2471123721 hasRelatedWork W2562314043 @default.
• W2471123721 hasRelatedWork W2571094262 @default.
• W2471123721 hasRelatedWork W2579156720 @default.
• W2471123721 hasRelatedWork W2580497187 @default.
• W2471123721 hasRelatedWork W2583620316 @default.
• W2471123721 hasRelatedWork W2588512316 @default.
• W2471123721 hasRelatedWork W2595210719 @default.
• W2471123721 hasRelatedWork W2922858893 @default.
• W2471123721 hasRelatedWork W2979732157 @default.
• W2471123721 hasRelatedWork W2980195347 @default.
• W2471123721 hasRelatedWork W2989326485 @default.
• W2471123721 isParatext "false" @default.
• W2471123721 isRetracted "false" @default.
• W2471123721 magId "2471123721" @default.
• W2471123721 workType "article" @default.